189 related articles for article (PubMed ID: 24710512)
1. Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells.
Li W; Liu J; Jackson K; Shi R; Zhao Y
PLoS One; 2014; 9(4):e94079. PubMed ID: 24710512
[TBL] [Abstract][Full Text] [Related]
2. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
3. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Yang Q; Ji M; Guan H; Shi B; Hou P
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
5. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
[TBL] [Abstract][Full Text] [Related]
6. Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation.
Li W; Zhang C; Ren A; Li T; Jin R; Li G; Gu X; Shi R; Zhao Y
PLoS One; 2015; 10(5):e0126459. PubMed ID: 25961580
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
8. Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
Li Y; Zhou W; Tang K; Chen X; Feng Z; Chen J
Oncol Rep; 2017 Oct; 38(4):2011-2022. PubMed ID: 28849180
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau.
Lin H; Zheng L; Li S; Xie B; Cui B; Xia A; Lin Z; Zhou P
Phytother Res; 2018 Apr; 32(4):667-671. PubMed ID: 29368408
[TBL] [Abstract][Full Text] [Related]
11. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
12. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
13. High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel.
Luo Y; Wang X; Wang H; Xu Y; Wen Q; Fan S; Zhao R; Jiang S; Yang J; Liu Y; Li X; Xiong W; Ma J; Peng S; Zeng Z; Li X; Phillips JB; Li G; Tan M; Zhou M
PLoS One; 2015; 10(9):e0138955. PubMed ID: 26406239
[TBL] [Abstract][Full Text] [Related]
14. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
15. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
Li W; Liu J; Zhao Y
Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
[TBL] [Abstract][Full Text] [Related]
16. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
Li B; Yuan Z; Jiang J; Rao Y
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
[TBL] [Abstract][Full Text] [Related]
18. Difluoromethylornithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells.
Das B; Rao AR; Madhubala R
Oncol Res; 1997; 9(11-12):565-72. PubMed ID: 9563003
[TBL] [Abstract][Full Text] [Related]
19. Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7.
Shahsavari Z; Karami-Tehrani F; Salami S
Anticancer Agents Med Chem; 2018; 18(2):245-254. PubMed ID: 28933271
[TBL] [Abstract][Full Text] [Related]
20. Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.
Androic I; Krämer A; Yan R; Rödel F; Gätje R; Kaufmann M; Strebhardt K; Yuan J
BMC Cancer; 2008 Dec; 8():391. PubMed ID: 19113992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]